STOCK TITAN

Windward Bio lists Omega funds' preferred-share stakes

Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
3

Rhea-AI Filing Summary

WINDWARD BIO GROUP AG (WWB) lists preferred-share holdings held by Omega Fund VII, L.P. and Omega Fund VIII, L.P., in connection with director Otello Stampacchia. As of November 12, 2026, Omega VII held 1,262,628 Series A and 531,632 Series B Preferred Shares; Omega VIII held 1,262,626 Series A and 531,634 Series B Preferred Shares. Stampacchia disclaims beneficial ownership except to the extent of any pecuniary interest.

Each Series A and Series B Preferred Share automatically converts into Common Shares on a 1 to 1 basis immediately prior to the closing of the issuer’s initial public offering.

Insider Stampacchia Otello
Role Director
Type Security Shares Price Value
Holding Series A Preferred Shares F1, F2 -- -- --
Holding Series A Preferred Shares F1, F3 -- -- --
Holding Series B Preferred Shares F1, F2 -- -- --
Holding Series B Preferred Shares F1, F3 -- -- --
Holdings: Series A Preferred Shares — 1,262,628 shares (Indirect, By Omega Fund VII, L.P.); Series A Preferred Shares — 1,262,626 shares (Indirect, By Omega Fund VIII, L.P.); Series B Preferred Shares — 531,632 shares (Indirect, By Omega Fund VII, L.P.); Series B Preferred Shares — 531,634 shares (Indirect, By Omega Fund VIII, L.P.)
Footnotes (3)
  1. F1. Each Series A Preferred Share and Series B Preferred Share will automatically convert into the number of Common Shares on a 1 to 1 basis immediately prior to the closing of the Issuer's initial public offering and has no expiration date.
  2. F2. Shares held directly by Omega Fund VII, L.P. ("Omega VII"). Omega Fund VII GP, L.P. ("Omega VII GP") is the sole general partner of Omega VII. Omega Fund VII GP Manager, Ltd. ("Omega VII Manager") is the sole general partner of Omega VII GP. The Reporting Person is a director of Omega VII Manager and disclaims beneficial ownership of the shares held by Omega VII except to the extent of his pecuniary interest therein, if any.
  3. F3. Shares held directly by Omega Fund VIII, L.P. ("Omega VIII"). Omega Fund VIII GP, L.P. ("Omega VIII GP") is the sole general partner of Omega VIII. Omega Fund VIII GP Manager, Ltd. ("Omega VIII Manager") is the sole general partner of Omega VIII GP. The Reporting Person is a director of Omega VIII Manager and disclaims beneficial ownership of the shares held by Omega VIII except to the extent of his pecuniary interest therein, if any.
Omega Fund VII Series A Preferred Shares 1,262,628 shares Held as of November 12, 2026
Omega Fund VII Series B Preferred Shares 531,632 shares Held as of November 12, 2026
Omega Fund VIII Series A Preferred Shares 1,262,626 shares Held as of November 12, 2026
Omega Fund VIII Series B Preferred Shares 531,634 shares Held as of November 12, 2026
Series A Preferred Shares financial
"Each Series A Preferred Share"
Series A preferred shares are an early-stage class of ownership sold to investors that gives them special protections and payment priority over regular common stock. Think of them as a safer seat on a bus: if the company earns money or is sold, holders get paid before ordinary shareholders, and they often can convert to common shares later to share upside; that mix of safety and growth potential helps investors manage risk and reward.
Series B Preferred Shares financial
"Each Series B Preferred Share"
Series B preferred shares are a class of company stock issued during a later round of private financing that gives investors priority over common shareholders for payouts and protections if the company is sold or liquidated. Think of them as a VIP ticket that often includes a fixed claim on returns, possible regular payments, and the option to convert into regular shares; that mix of safety and upside helps investors assess risk and potential reward.
1 to 1 basis technical
"on a 1 to 1 basis"
initial public offering financial
"closing of the Issuer's initial public offering"
An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many WWB preferred shares are held by Omega Fund VII and Omega Fund VIII?

As of November 12, 2026, Omega Fund VII, L.P. held 1,262,628 Series A Preferred Shares and 531,632 Series B Preferred Shares; Omega Fund VIII, L.P. held 1,262,626 Series A Preferred Shares and 531,634 Series B Preferred Shares.

How do WWB Series A and Series B Preferred Shares convert?

Each Series A Preferred Share and Series B Preferred Share automatically converts into Common Shares on a 1 to 1 basis immediately prior to the closing of the issuer’s initial public offering.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Stampacchia Otello

(Last)(First)(Middle)
C/O WINDWARD BIO GROUP AG
AESCHENPLATZ 6

(Street)
BASEL4052

(City)(State)(Zip)

SWITZERLAND

(Country)
2. Date of Event Requiring Statement (Month/Day/Year)
11/12/2026
3. Issuer Name and Ticker or Trading Symbol
WINDWARD BIO GROUP AG [ WWB ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Series A Preferred Shares (1) (1)Common Shares1,262,628(1)IBy Omega Fund VII, L.P.(2)
Series A Preferred Shares (1) (1)Common Shares1,262,626(1)IBy Omega Fund VIII, L.P.(3)
Series B Preferred Shares (1) (1)Common Shares531,632(1)IBy Omega Fund VII, L.P.(2)
Series B Preferred Shares (1) (1)Common Shares531,634(1)IBy Omega Fund VIII, L.P.(3)
Explanation of Responses:
1. Each Series A Preferred Share and Series B Preferred Share will automatically convert into the number of Common Shares on a 1 to 1 basis immediately prior to the closing of the Issuer's initial public offering and has no expiration date.
2. Shares held directly by Omega Fund VII, L.P. ("Omega VII"). Omega Fund VII GP, L.P. ("Omega VII GP") is the sole general partner of Omega VII. Omega Fund VII GP Manager, Ltd. ("Omega VII Manager") is the sole general partner of Omega VII GP. The Reporting Person is a director of Omega VII Manager and disclaims beneficial ownership of the shares held by Omega VII except to the extent of his pecuniary interest therein, if any.
3. Shares held directly by Omega Fund VIII, L.P. ("Omega VIII"). Omega Fund VIII GP, L.P. ("Omega VIII GP") is the sole general partner of Omega VIII. Omega Fund VIII GP Manager, Ltd. ("Omega VIII Manager") is the sole general partner of Omega VIII GP. The Reporting Person is a director of Omega VIII Manager and disclaims beneficial ownership of the shares held by Omega VIII except to the extent of his pecuniary interest therein, if any.
/s/ Scott Applebaum, Attorney-in-Fact11/12/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Keep reading